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Table 1.1 Levels of evidence and grades of recommendation
based on the Oxford Centre for Evidence Based Medicine (for
details see http://www.cebm.net/levels_of_evidence.
asp#refs)
Level Diagnostic study Therapeutic study
1a Systematic review (SR)
with homogeneity of level
1 diagnostic studies
Systematic review (SR)
with homogeneity of
randomized controlled
trials (RCTs)
1b Validating cohort study
with good reference
standards
Individual RCT (with
narrow Confidence
Interval)
1c Specificity is so high that a
positive result rules in the
diagnosis (“SpPin”) or
sensitivity is so high that a
negative result rules out
the diagnosis (“SnNout”)
All or none
2a SR with homogeneity of
level N2 diagnostic studies
SR (with homogeneity )
of cohort studies
2b Exploratory cohort study
with good reference
standards
Individual cohort study
(including low quality
RCT; e.g., b80%
follow up)
2c “Outcomes” research;
ecological studies
3a SR with homogeneity of 3b
and better studies
SR with homogeneity of
case-control studies
3b Non-consecutive study; or
without consistently
applied reference
standards
Individual case-control
study
4 Case-control study, poor
or non-independent
reference standard
Case-series (and poor
quality cohort and case-
control studies)
5 Expert opinion without
explicit critical appraisal,
or based on physiology,
bench research or “first
Expert opinion without
explicit critical appraisal,
or based on physiology,
bench research or “first
3ECCO Consensus on UC: Definitions and diagnosis1. Definitions
1.1. Introduction
Ulcerative colitis is a life long disease arising from an
interaction between genetic and environmental factors, but
observed predominantly in the developed countries of the
world. The precise aetiology is unknownand thereforemedical
therapy to cure the disease is not yet available. Within Europe
there is a North–South gradient, but the incidence appears to
have increased in Southern and developing countries in recent
years.1,2 Patients may live with a considerable symptom
burden despite medical treatment (66% describe interference
with work and 73%with leisure activities3) in the hope that the
aetiology of ulcerative colitis will shortly be revealed and a
cure emerges. Although this is conceivable in the next decade,
clinicians have to advise patients on the basis of information
available today. Despite randomized trials there will always be
many questions that can only be answered by the exercise of
judgement and opinion. This leads to differences in practice
between clinicians, which may be brought into sharp relief by
differences in emphasis between countries.
The Consensus endeavours to address these differences. The
Consensus is not meant to supersede the guidelines of different
countries (such as those from theUK,4 or Germany5), which reach
broadly the same conclusions since they are, after all, based on
the sameevidence.Rather, theaimof theConsensus is topromote
a European perspective on the management of ulcerative colitis
(UC) and its dilemmas. Since the development of guidelines is an
expensive and time-consuming process, it may help to avoid
duplication of effort in the future. A European Consensus is also
considered important because an increasing number of thera-
peutic trials recruit from Central and Eastern European countries
where practice guidelines have yet to be published.
This document sets out the current European Consensus on
the diagnosis andmanagement of UC, reached by the European
Crohn's and Colitis Organisation (ECCO) at a meeting held in
Berlin on 20th October 2006. ECCO is a forum for specialists in
inflammatory bowel disease from 23 European countries. Like
the initial Consensus on the management of Crohn's disease,6
the current Consensus is grouped into three parts: definitions
and diagnosis; current management; and management of
special situations. This first section concerns aims, methods
and definitions of the Consensus, as well as classification,
diagnosis, imaging and pathology of UC. The second section on
current management includes treatment of active disease,
maintenance ofmedically-induced remission and surgery ofUC.
The third section on special situations includes pouch disorders,
cancer surveillance, pregnancy, paediatrics, psychosomatics,
extra-intestinal manifestations and alternative therapy.
The strategy to reach the Consensus involved five steps:
principles” principles”
Grades of recommendation
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolations from
level 1 studies
C Level 4 studies or extrapolations from level 2 or 3
studies
D Level 5 evidence or troublingly inconsistent or
inconclusive studies of any level1. Relevant questions on each of 14 separate topics concern-
ing diagnosis and treatment of UC were devised by the
chairmen and their working party. The questions were
focused on current practice and areas of controversy in the
task force topic, sent around to the other chairmen to avoid
duplication, and then to all 59 participants in the Consensus
conference. Participants were asked to answer the ques-
tions basedon their experienceaswell as evidence from the
literature (Delphi procedure).72. In parallel, the working parties performed a systematic
literature search of their topic with the appropriate key
words using Medline/Pubmed and the Cochrane database,
as well as their own files. The evidence level (EL) was
graded (Table 1.1) according to the Oxford Centre for
Evidence Based Medicine.8
3. Provisional guideline statements on their topic were then
written by the chairmen, based on answers to the question-
naire as well as the literature evidence and were circulated
Table 1.3 Disease activity in ulcerative colitis, adapted
from Truelove and Witts'13
Mild Moderate ‘in
between
mild and
severe’
Severe
Bloody stools/day b4 4 or more if ≥6 and
Pulse b90 bpm ≤90 bpm N90 bpm or
Temperature b37.5 °C ≤37.8 °C N37.8 °C or
Haemoglobin N11.5 g/dL ≥10.5 g/dL b10.5 g/dL or
ESR b20 mm/h ≤30 mm/h N30 mm/h or
or CRP Normal ≤30 mg/L N30 mg/L
Table 1.4 Mayo score [14,15 and www.gastrojournal.org for
4 E.F. Stange et al.first among the working party and then among the
participants.
4. The working parties then met in Berlin on the 20 October
2006 to agree the statements. Participants gathered under
the Chairmanship of EF Stange and SPL Travis to agree the
final version of each guideline statement. Technically this
was donebyprojecting the statements and revising themon
screen until a Consensus was reached. Consensus was
defined as agreement by N80% of participants, termed a
Consensus Statement and numbered for convenience in the
document. Each recommendation was graded (RG) accord-
ing to the Oxford Centre for Evidence Based Medicine,8
based on the level of evidence (Table 1.1).
5. The final document on each topic was written by the
chairmen in conjunction with their working party. Con-
sensus guideline statements in bold are followed by
comments on the evidence and opinion. Statements are
intended to be read in context with qualifying comments
and not read in isolation. The final text was edited for
consistency of style by SPLTravis and EF Stangebeforebeing
circulated and approved by the participants. In some areas
the level of evidence is generally low, which reflects the
paucity of randomized controlled trials. Consequently
expert opinion is included where appropriate.
1.2. Definitions
Common agreement has been reached by ECCO about
frequently used terms. While the significance of some terms
(such as ‘early-’ or ‘pattern of relapse’) is undetermined, such
terms reflect clinical decision-making (such as when to start
immunomodulators) and are considered helpful as a conse-
quence. The arbitrariness of some of the definitions is
recognised, but the Consensus considers it useful to agree the
terminology.
Ulcerative colitis (UC) is a chronic inflammatory condition
causing continuous mucosal inflammation of the colon with-
out granulomas on biopsy, affecting the rectum and a variable
extent of the colon in continuity, which is characterised by a
relapsing and remitting course.9
Colitis yet to be classified is the term best suited for the
minority of cases where a definitive distinction between UC,
Crohn's disease, or other cause of colitis cannot be made
after the history, endoscopic appearances, histopathology of
multiple mucosal biopsies and appropriate radiology have
been taken into account.9,10
Indeterminate colitis is a termpreserved for pathologists to
describe a colectomy specimenwhich has overlapping featuresTable 1.2 Distribution of ulcerative colitis (from9)
Term Distribution Description
E1 Proctitis Involvement limited to the rectum (i.e.
proximal extent of inflammation is distal
to the rectosigmoid junction)
E2 Left-sided Involvement limited to the proportion of
the colon distal to the splenic flexure
(analogous to ‘distal’ colitis)
E3 Extensive Involvement extends proximal to the
splenic flexure, including pancolitisof ulcerative colitis and Crohn's disease.10,11 It has distinct
prognostic factors related to further surgery (Section 7.5.7,
first following paper in same issue).
1.2.1. Distribution of disease (see Section 2.1)
The Montreal classification (Table 1.29) for defining the
distribution of disease was favoured by 52/59 participants.
This is taken to mean the maximal, macroscopic extent of
disease at colonoscopy, since the long-term prognosis in the
past has used the extent of disease as defined by barium
enema. The implications of more extensive microscopic
disease are not understood. The poor correlation between
macroscopic andmicroscopic extent of disease (kappa=0.39) is
recognised.10 So too is the limitation of an extent-based
classificationwhen theextent varies over time, underlining the
dynamic nature of inflammatory bowel disease.12
1.2.2. Active disease
For the purposes of this Consensus, clinical disease activity is
grouped into remission, mild, moderate and severe. Precise
definitions of disease activity are appropriate, since confu-
sion arises if the terms are used to refer only to the least,
intermediate or most severe third of cases that the physician
can recall at the time. Among Consensus participants, 31/59
considered Truelove and Witts' criteria useful in clinical
practice (summarized, Table 1.313), in conjunction with sig-
moidoscopy to confirm active colitis.
16/59 favoured the Mayo score (Table 1.4),14 with its
modifications.15 The value of the different indices for the
purpose of clinical trials is beyond the scope of the Consensus,full details]
Mayo
index
0 1 2 3
Stool
frequency
Normal 1–2/day
Nnormal
3–4/day
Nnormal
5/day
Nnormal
Rectal
bleeding
None Streaks Obvious Mostly blood
Mucosa Normal Mild
friability
Moderate
friability
Spontaneous
bleeding
Physician's
global
assessment
Normal Mild Moderate Severe
5ECCO Consensus on UC: Definitions and diagnosisbut has recently been reviewed.15 ECCO recognises the need
to validate clinical and endoscopic scoring systems.
The Montreal classification (Table 1.5)9,10 is largely based
on Truelove and Witts' criteria, since this reflects clinical
practice.
Severe colitis (or ‘acute severe colitis’) is preferred to
‘fulminant’ colitis, because the term ‘fulminant’ is ill-defined.
It was coined in 1950 when it referred to a single attack going
on to death within 1 year,16 which no longer has relevance
today. Severe colitis defined according to Truelove and Witts'
criteria (Table 1.3 and Section 5.1, first following paper in
same issue) are easy to apply in outpatients, determine a
course of action (hospital admission for intensive treatment)
and anoutcome (only 70% respond to intensive therapy). These
criteria are recommended for identifying acute severe colitis
by The American College of Gastroenterology (ACG)17 and the
Association of Coloproctology of Great Britain and Ireland
(ACPGBI),18 as well as ECCO.
Moderate colitis has become necessary to distinguish from
mildly active disease, because the efficacy of some treatments
may differ (Section 5, first following paper in same issue). The
simplest clinical measure to distinguish moderate from mildly
active colitis is the presence of mucosal friability (bleeding on
light contact with the rectal mucosa at sigmoidoscopy). The
technique of assessing mucosal friability at flexible sigmoido-
scopy has yet to be standardised. One approach is to apply
sufficient pressure on themucosawith closed biopsy forceps to
create a dimple, maintain the pressure for 3 s and then define
friability if bleeding occurs from the pressure point. This has
yet to be validated.
1.2.3. Remission
Remission is defined as complete resolution of symptoms and
endoscopic mucosal healing (Section 2.2.4). Combining
clinical and endoscopy is appropriate for clinical trials,15,19
but remission rates vary by as much as two-fold depending on
the definition of remission used in the trial.20 In clinical
practice, 33/59 participants agreed that ‘remission’meant a
stool frequency ≤3/day with no bleeding and no urgency.
Remission defined by individual patients has an 86% sensitiv-
ity and 76% specificity for a regulatory-defined remission
(absence of visible blood and absent mucosal friability),
indicating that sigmoidoscopy to confirm mucosal healing is
generally unnecessary in practice.21Table 1.5 Montreal classification of disease activity in
ulcerative colitis9
S0 S1 S2 S3
Remission Mild Moderate Severe
Stools/day Asymptomatic ≤4 N4 ≥6 and
Blood May be
present
Present Present
Pulse All
normal
Minimal,
or no
signs of
systemic
toxicity
N90 bpm or
Temperature N37.5 °C or
Haemoglobin b10.5 g/dL or
ESR N30 mm/h1.2.4. Response
Response is defined as clinical and endoscopic improvement,
depending (for the purpose of clinical trials) on the activity
index used. In general, this means a decrease in the activity
index of N30%, plus a decrease in the rectal bleeding and
endoscopy subscores, but there are many permutations.15
1.2.5. Relapse
The term relapse is used to define a flare of symptoms in a
patient with established UC who is in clinical remission, either
spontaneously or after medical treatment. In the Consensus,
47/59 considered rectal bleeding an essential component of
relapse, and 29/59 believed that a combination of rectal
bleeding with an increase in stool frequency and abnormal
mucosa at sigmoidoscopy was necessary to define relapse. In
clinical trials, the criteria for relapse should be predefined
with the score that is being used for an individual study.15
1.2.6. Early relapse
An arbitrary, but clinically relevant period of b3 months after
achieving remission on previous therapy defines early
relapse. The therapeutic significance needs to be defined.
1.2.7. Pattern of relapse
Relapse may be infrequent (≤1/year), frequent (≥2 relapses/
year), or continuous (persistent symptoms of active UCwithout
a period of remission).22 Although the terms are arbitrary, they
are considered clinically relevant. An alternative approach that
defines disease activity over a 5 year period has been proposed
(Section 6.1.2, first following paper in same issue), but this
seems more relevant to epidemiological studies, since what
matters for everyday practice is what is likely to happen in the
next year. The prognostic significance needs to be determined.
Nevertheless, care should be taken to distinguish between
terms that describe disease activity at a point in time and those
that describe the longitudinal pattern (or ‘behaviour’) of the
disease (Sections 1.2.2 and 2.2.1). The term ‘chronic active
disease’ has been used in the past to define a patient who is
dependent on, refractory to, or intolerant of steroids, or who
has diseaseactivity despite immunomodulators. Since this term
is ambiguous it is best avoided. Instead, arbitrary, but more
precise definitions are preferred, including steroid-refractory
or steroid-dependence.
1.2.8. Steroid-refractory colitis
Patients who have active disease despite prednisolone up to
0.75 mg/kg/day over a period of 4 weeks. This was agreed by
45/58 participants, is consistentwith the definition for steroid-
refractory Crohn's disease6 and others.15 The definition is
however likely to evolve, with a reduction in the duration of
steroid therapy as the threshold for biologic therapy changes.
1.2.9. Steroid-dependent colitis
Patients who are either
i) unable to reduce steroids below the equivalent of pre-
dnisolone 10 mg/day within 3 months of starting steroids,
without recurrent active disease, or
ii) who have a relapse within 3 months of stopping steroids.
This was agreed by 52/58 participants and is consistent
with the definition for steroid-dependent Crohn's disease,6
Table 2.1 Endoscopic scores for ulcerative colitis commonly used in clinical trials
Score 0 1 2 3
Baron et al.156 Normal: matt mucosa,
ramifying vascular
pattern clearly visible,
no spontaneous bleeding,
no bleeding to
light touch
Abnormal,
but non-haemorrhagic:
appearances
between 0 and 2
Moderately haemorrhagic:
bleeding to light touch,
but no spontaneous bleeding
seen ahead of the instrument
on initial inspection
Severely haemorrhagic:
spontaneous bleeding
seen ahead of instrument
at initial inspection and
bleeds to light touch
Schroeder et
al.158
Normal or inactive disease Mild (erythema,
decreased
vascular pattern,
mild friability)
Moderate (marked erythema,
absent vascular pattern,
friability, erosions)
Severe (spontaneous
bleeding, ulceration)
Feagan et al.159 Normal, smooth, glistening
mucosa, with vascular
pattern visible; not friable
Granular mucosa;
vascular pattern
not visible; not
friable; hyperaemia
As 1, with a friable mucosa,
but not spontaneously
bleeding
As 2, but mucosa
spontaneously bleeding
6 E.F. Stange et al.although an alternative definition of relapse within 30 days
of completing a course of steroids, or steroids at a dose of
15–25 mg/day for at least 6 months has been proposed.15 As
with steroid-refractoriness, the definition is likely to evolve
as the threshold for biologic therapy changes.
The ECCO definition of steroid-dependence requires that
the total duration of steroids does not exceed 3months before
a threshold equivalent to prednisolone 10 mg/day is reached.
Patients are still considered steroid-dependent if they relapse
within 3 months of stopping steroids. Although these limits are
arbitrary, they serve as guidance for clinical practice and may
be used for uniformity in clinical trials. The aim should be to
withdraw steroids completely.
1.2.10. Immunomodulator-refractory colitis
Patients who have active disease or relapse in spite of
thiopurines at an appropriate dose for at least 3 months (i.e.
azathioprine 2–2.5 mg/kg/day or mercaptopurine 0.75–1mg/
kg/day in the absence of leucopenia). The definition is
arbitrary, but has increasing clinical relevance when deciding
on the place of biological therapy or surgery.
1.2.11. Refractory distal colitis
Defined as persistent symptoms due to colonic inflammation
confined to the rectum (proctitis), or left side of the colon (more
commonly the rectosigmoid colon), despite treatment with oral
and topical steroids for 6–8 weeks. This represents a common
clinicaldilemma,althoughwhether it isa separateentity isunclear.
1.2.12. New patient
A patient with active UC presenting at, or shortly after
diagnosis, with no previous therapy for UC.
1.2.13. Alternative therapy
One that is used in place of conventional medicine.
1.2.14. Complementary therapies
Similar treatments used alongside conventional medicine
(see section on Alternative therapies for comment).
1.2.15. Expert opinion
The term ‘expert’ is used here to refer to the opinion of the
specialists in inflammatory bowel disease representing multi-ple disciplines from 23 European countries who contributed to
the ECCO Consensus. In some sections opinions from individual
members of other expert bodies were obtained, including
individuals of the European Society of Pathology (ESP) working
group on Digestive Diseases, the European Society of Gastro-
intestinal and Abdominal Radiology (ESGAR) and the European
Society of Paediatric Gastroenterology Hepatology and Nutri-
tion (ESPGHAN).
2. Classification
2.1. Classification according to disease extent
ECCO Statement 2A
The extent of ulcerative colitis influences the pa-
tient's management. Disease extent influences the
treatment modality and determines if oral and/or
topical therapy is initiated [EL1b, RG B]. Disease
extent influences start and frequency of surveillance
[EL2, RG B]. Therefore, a classification according to
extent of disease is recommended [EL5, RG D].
The preferred classification is an endoscopic classifi-
cation as outlined in the Montreal classification into
ulcerative proctitis (limited to the rectum), left-sided
colitis (up to the splenic flexure) andextensive colitis,
and by maximal extent upon follow up [EL5, RG D]
There are several reasons why patients with ulcerative
colitis (UC) should be classified according to disease extent.
First, the extent of inflammation will influence the patient's
management and influence the choice of delivery system for a
given therapy. Indeed, the location and extent of the colitis
will determine if oral and/or topical therapy is initiated. For
instance, topical therapy in the form of suppositories (for
proctitis) or enemas (for left-sided colitis) is often the first line
choice, but oral therapy — often combined with topical
therapy is appropriate for extensive colitis (beyond the splenic
flexure) [EL1b, RG B]. Second, the extent of colitis influences
the start and the frequency of surveillance [EL2, RG B]. In the
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one of the risk factors for development of colorectal cancer in
3117 UC patients followed up from 1 to 60 years after diag-
nosis. Whereas no increased relative risk (RR) was attributed
to disease confined to the rectum, the RR for left-sided colitis
and extensive colitis (previously called pancolitis) were 2.8
(95%CI 1.6–4.4) and 14.8 (95%CI 11.4–18.9) respectively.
Therefore, patients with left-sided and extensive colitis are
generally advised to have surveillance colonoscopy from 8 to
10 years after symptom onset, but patients with proctitis do
not need surveillance (Section 9.2, second following paper in
same issue). The contribution of disease extent at diagnosis to
the risk of malignancy has been confirmed more recently by
the EC-IBD study group.24
Once agreed that classification according to disease
extent is important, the next question is which classification
best to use? The Consensus group agreed that the preferred
classification is an endoscopic classification into proctitis,
left-sided colitis and extensive colitis (beyond the splenic
flexure), as defined by the Montreal Working Group on the
Molecular classification of IBD9,10 (Section 1.2, Table 1.2). A
fourth extent-group of proctosigmoiditis was abandoned,
because it lacks any scientific background and does not have
direct therapeutic consequences.
2.2. Classification according to disease severity
ECCO Statement 2B
Classification of ulcerative colitis based on disease
severity is useful for clinical practice and dictates
the patient's management [EL1b,RG B]. Disease se-
verity influences the treatment modality and deter-
mines if no, oral, intravenous or surgical therapy is
initiated. Indices of disease severity have not been
adequately validated. Clinical, laboratory, imaging
and endoscopic parameters, including histopathol-
ogy assist physicians in patients' management [EL 2,
RG B]. There is no fully validated definition of remis-
sion. The best way of defining remission is a
combination of clinical parameters (i.e. stool fre-
quency ≤3/day with no bleeding) and a normal
mucosa at endoscopy [EL5, RG D] (majority vote)2.2.1. Activity and pattern of disease
In a population-based study from Copenhagen County,
Langholz et al. showed that approximately 50% of patients
will be in clinical remission every year at any time.25 How-
ever, the cumulative probability of a relapsing course after
25 years of follow up amounted to 90%. The disease activity
in the first 2 years after diagnosis indicated (with 70–80%
probability) an increased probability of 5 consecutive years
of active disease and was therefore judged to be a good
parameter to predict the future pattern of disease. This is a
helpful practical point to be used by clinicians when advising
patients and making management decisions.
A distinction should be made between disease activity at a
point in time (remission, mild, moderate, severe) and the
response of disease to treatment (using terms such as 5-ASAor steroid responsive, steroid-refractory, biologic dependent
etc.). The two should not be confused by sloppy terminology
that describesmildly active disease that is steroid-dependent
as ‘severe’. The consequences (biologic therapy, colectomy)
may indeed be considered ‘severe’, but disease activity
remains mild. See also Section 3.5.
2.2.2. Choice of index
A classification of UC based on disease activity and severity is
important because it influences patient's management. The
severity of the inflammation will be determined if no
therapy, oral therapy, intravenous or surgical therapy is
initiated in a given patient. Over the years, many disease
activity indices or criteria have been proposed (see Section
1.2.2 and Ref. 15 for a review), but none has been
adequately validated. The Consensus recognises the need
for validated clinical and endoscopic indices that relate to
outcome or treatment decisions. Although modifications of
the original Truelove and Witts' criteria (Section 1.2.1, Table
1.3) are used in daily practice, the modified Mayo score
(Section 1.2.1, Table 1.4) is used more frequently in current
clinical trials.15 For clinical practice, the Consensus group
judged that a combination of clinical features, laboratory
findings, imaging modalities and endoscopic parameters,
including histopathology will all assist physicians in their
patients' management. Endoscopic scoring is illustrated in
Section 3.5 and Table 2.1. There is a need for systematic
study of this area.
2.2.3. Clinical and laboratory markers of severity
Among objective clinical features, bloody stool frequency,
body temperature and heart rate are good predictors of
outcome. Laboratory markers have been studied intensively
with varying degrees of success. The widely used acute phase
protein C-reactive protein in this respect is a less good
marker for assessing disease activity in UC than Crohn's
disease, except for acute severe colitis, where it has
established value in both adults and children.26–28 A raised
CRP N45 mg/L at day 3 following hospital admission for
severe colitis together with more than 8 stools a day is highly
predictive for need for colectomy (Section 5.2.5, first
following paper in same issue). Other positive (erythrocyte
sedimentation rate, serum procalcitonin29) or negative
(albumin) acute phase proteins have been studied, but
none has demonstrated clear superiority (for review see
Ref. 30). More recently, faecal markers have demonstrated
promising results. The most studied markers are faecal
calprotectin and lactoferrin, but elastase and the more
recent marker S100A12 have also shown accuracy at
detecting colonic inflammation.31–35 It must be stressed
however that none of these markers is specific for UC, since
they merely represent colonic inflammation with an influx of
neutrophils into the gut mucosa, with subsequent shedding
of their granules into the gut lumen.
2.2.4. Remission
As with the definition of disease activity, there has also not
been a fully validated definition of remission. The Consensus
group agreed that the best way of defining remission is a
combination of clinical parameters (stool frequency≤3/day
with no bleeding) and normal or quiescent mucosa at endo-
scopy (majority vote, Section 1.2.3).20
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concomitant primary sclerosing cholangitis
ECCO Statement 2C
A classification of UC according to age at onset is
not useful [EL2; RG C]. Classification of UC
according to the concomitant presence of PSC is
important because it influences patients' manage-
ment (surveillance) [EL2; RG C]
A classification according to age at onset is not useful
because it does not affect patient's management. All current
available therapies for UC have shown equal efficacy in children
with young age at onset compared to adults. The risk of colo-
rectal cancer in patients with the onset of UC in childhood
almost certainly reflects the duration of disease (Section 9.1.2,
second following paper in same issue). However, concomitant
primary sclerosing cholangitis (PSC) is an important feature to
take into account when giving care to patients with UC given its
increased associated risk for colorectal cancer.23,36 This
influences decisions on surveillance colonoscopy (Sections
9.1.2 and 9.2.4, second following paper in same issue).
2.4. Use of molecular markers
ECCO Statement 2D
No evidence-based recommendation can be made
to implement the routine clinical use of molecular
markers (genetic, serologic) for the classification
of UC patients [EL2, RG C]
2.4.1. Serology
A number of (auto)antibodies have been described in UC
patients, of which the atypical perinuclear anti-neutrophil
cytoplasmatic antibodies (pANCAs) are best known. Positive
pANCA serology is found in approximately 50–60% of pa-
tients, although large variability exists due to differences in
methodology.37,38 Overall, pANCA has shown good accuracy to
differentiate CD from UC,39–41 but their sensitivity is far from
high enough to justify their use in diagnosis. These antibodies
also lack accuracy in patients with colitis yet to be classified,
where these markers would be of greatest clinical value.42 A
number of other antimicrobial antibodies as ASCA, OmpC, I2,
cBir anti-flagellin, ALCA, ACCA, are found mainly in patients
with Crohn's disease.43–46
2.4.2. Genotyping
The very active field of IBD genetics has led to the iden-
tification of several genes, most of which are implicated in a
susceptibility to Crohn's disease, but some also linked to UC.
TheHLA region is without any doubt the regionmost associated
with UC,47 but the Interleukin-23 Receptor (IL23R) gene on
chromosome 1,48 the DLG5 gene on chromosome 10,49 the
Multidrug Resistance gene (MDR)-1 and the Toll like Receptor
(TLR) genes, have shown associations with UC.50–58 Since UC
is a complex multifactorial disease, the disease-associated
mutations in these genes will never be sufficient to causedisease, nor will the absence of mutations be a guarantee of
remaining free of disease. Therefore, testing for these genetic
variants is not recommended for clinical purposes.
3. Diagnosis and imaging
3.1. Introduction
Ulcerative colitis (UC) primarily presents in late adolescence
and early adulthood, although the diagnosis may be made at
any age. A small peak in incidence has been demonstrated in
some populations after the fifth decade of life.59 Ulcerative
colitis appears to affect both sexes equally. The inflammation
characteristically commences in the rectum and extends
proximally in a continuous, confluent and concentric manner
to affect a variable extent of the colon, or its entire mucosal
surface. The definitions and classification of the extent of UC
are covered in Sections 1.1 and 2.1 (Table 1.2).9 The proximal
extent of inflammation may progress or regress over time, but
after disease regression the distribution of inflammation tends
to match the extent of previous episodes in the event of
relapse. The view that UC represents continuous colonic in-
flammation has, however, been challenged by reports of a
rectal sparing variant and peri-appendiceal patchy inflamma-
tion.60 Symptoms dependon the extent and severity of disease,
extra-intestinal manifestations and concurrent therapy.
Enteric pathogens may alter the clinical presentation.
3.2. Clinical features and risk factors
3.2.1. Clinical features of ulcerative colitisECCO statement 3A
Symptoms of ulcerative colitis are dependent upon
extent and severity of disease, and most commonly
include bloody diarrhoea, rectal bleeding, and/or
rectal urgency. Nocturnal defaecation is also often
reported. Systemic symptoms of malaise, anorexia,
or fever are features of a severe attack [EL5, RG D]
The primary presenting symptom of ulcerative colitis is
visible blood in the stools and is reported by more than 90% of
patients. Associated symptoms generally reflect the en-
doscopic severity of the disease as a measure of mucosal
damage and may differ according to disease extent.61–71
Loose stools (or a decrease in stool consistency) formore than
six weeks differentiates UC frommost infectious diarrhoea.72
Patients with extensive active UC present with chronic
diarrhoea almost invariably associated with rectal bleeding,
or at least visible blood in the stools. Such patients also
describe rectal urgency, tenesmus, passage of mucopurulent
exudates, nocturnal defaecation and crampy abdominal pain,
or ache over the left iliac fossa prior to and relieved by
defaecation. In contrast, patients with proctitis usually
present with rectal bleeding, urgency, tenesmus, and
occasionally severe constipation.64,66 Anal and minor peria-
nal lesions may complicate severe diarrhoea, but although
simple fistulae may occasionally occur in UC, recurrent or
complex perianal fistulae should always raise the suspicion of
Crohn's colitis.
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present for weeks or even months before medical advice is
sought. The disease may present with intermittent episodes
of symptoms or as a severe attack (in about 15%) with sys-
temic symptoms includingweight loss, fever and tachycardia,
or even nausea and vomiting.73 Extra-intestinal manifesta-
tions, especially an axial or peripheral arthropathy, episcler-
itis and erythema nodosum may accompany the presentation
in about 10% and rarely precede intestinal symptoms.74
Thromboembolism is more frequent in UC than the general
population, but is generally associated with active disease
and pancolitis.75
3.2.2. Risk factors for ulcerative colitis
ECCO statement 3B
Smoking exerts a universal protective effect
against developing UC and is associated with a
milder course of disease [EL2b, RGB]. Appendi-
cectomy has been shown to provide some protec-
tion against subsequently developing UC and in
reducing its severity if performed for ‘true’
appendicitis at a younger age [EL2b, RGB].
The use of non-selective NSAIDs is probably
associated with increased risk for exacerbating
UC [EL2b, RGB]. Short-term treatment with COX-2
inhibitors is probably safe [EL1b, RGB]. A family
history of CD or UC increases the risk for
developing UC in another family member [EL2b,
RGB]
Active tobacco smoking has a protective effect on the
development and severity of UC.76,77 In contrast, ex-smokers
have about a 70% greater risk of developing the disease, which
is often more extensive and refractory than in those who have
never smoked. Rates of hospital admission and colectomy
are also higher in ex-smokers than in never-smokers.78,79
Improvements in symptoms and amilder courseof diseasehave
been reported in ex-smokers who resume smoking,79,80 but
the effect is inconsistent. Smoking may also prevent the
development of primary sclerosing cholangitis (PSC), or
pouchitis after colectomy and ileal pouch anal anastomosis,
but this too has been challenged.81–83
Cohort studies and meta-analysis have suggested that
appendicectomy performed for true appendicitis at an early
age may be protective against the onset and subsequent
severity of UC. A 69% risk reduction has been reported for
appendicectomy, although a Danish cohort study failed to
confirm this.59,84–88 The protective effect of appendicectomy
is additional to that of smoking, but does not appear to
protect against the development of PSC.89 When appendi-
cectomy is performed after the onset of ulcerative colitis, the
effect (if any) on the course of the disease is far less clear.
Non-selective non-steroidal anti-inflammatory drugs
(NSAIDs) appear to carry a significant risk of exacerbating
ulcerative colitis. The magnitude of such risk has never been
adequately determined and it is unclear whether all patients
are affected to the same degree.90–93 In contrast, prelimin-
ary evidence from open-label studies and a double-blindcontrolled trial suggest that short-term treatment with
selective COX-2 inhibitors is safer.93,94 Nonetheless, pro-
longed usage is best avoided because of potential adverse
effects on other organ systems.
First-degree relatives of patients with UC have a 10–15-
fold risk of developing the disease.95 In a population-based
Danish cohort study, the relative risk for developing UCwas 10
amongst relatives with the disease.96 In other terms, the life
time risk of UC for a first degree relative is around 5%, or a 95%
chance of not developing the disease, which may help
reassure a parent with UC concerned about the risk to their
children. In familial cases of UC there is a slight female pre-
ponderance and younger age of onset compared to sporadic
cases.95,97
3.3. History, examination and diagnosis
3.3.1. Medical historyECCO statement 3C
A full medical history should include detailed
questioning about the onset of symptoms, particu-
larly recurrent episodes of rectal bleeding or bloody
diarrhoea, urgency, tenesmus, abdominal pain,
incontinence, nocturnal diarrhoea, and features
of extra-intestinal manifestations. Recent travel,
food intolerances, contact with enteric infectious
illnesses, medication (including antibiotics and
non-steroidal anti-inflammatory drugs), smoking
habit, sexual practice, family history of IBD and
previous appendicectomy should be explored [EL5,
RG D]
The diagnosis of UC is suspected from the clinical
symptoms (Section 3.2.1). Infectious or drug-induced
forms of colitis should be excluded. The absence of rectal
bleeding or symptoms in a current smoker should raise
questions about a diagnosis of UC, since Crohn's colitis would
be more likely. Enquiry should be made into the family
history and patients asked about possible ocular, oral, joint
or skin manifestations.4,98–102
3.3.2. Examination
ECCO statement 3D
In patients with UC physical examination should
include general well-being, pulse rate, body tem-
perature, blood pressure, body weight and height,
abdominal examination for distention and tender-
ness, perineal inspection, digital rectal examina-
tion, oral inspection, and check for eye, skin and/or
joint involvement. Physical examination may be
unremarkable in patients with mild or even
moderate disease [EL5, RG D]
Findings on physical examination depend on the extent and
severity of UC. Examination of patients with mild or moderate
activity is usually unremarkable, apart from blood on rectal
10 E.F. Stange et al.examination. Patients with a severe attack exhibit fever,
tachycardia, weight loss, colonic tenderness, abdominal
distension, or reduced bowel sounds103 (Section 1.1.2).
3.3.3. DiagnosisECCO statement 3E
A gold standard for the diagnosis of ulcerative
colitis is not available. The diagnosis should be
established by a combination of medical history,
clinical evaluation, and typical endoscopic and
histological findings. An infective cause should be
excluded. Where there is doubt about the diag-
nosis, endoscopic and histological confirmation is
necessary after an interval [EL5, RG D]
The natural history of UC is characterised by episodes of
relapse and periods of remission, and occasionally by an
unremitting, continuous course (about 5%). A single acute
episode followed by prolonged remission may also occur in
about 5%.25 The frequency of relapse (pattern of disease) is
usually defined in the first 3 years, and may be characterised
as frequent (≥2 relapses/year) or infrequent (≤1 relapse/
year,22 Sections 1.2.7 and 2.2.1).
It helps patients to establish the diagnosis, extent and
severity of the disease rapidly, because this influences treat-
ment options and possibly disease progression.71 Since there is
no single pathogenic marker, the diagnosis relies on a combina-
tion of medical history, endoscopic findings, histological fea-
tures on multiple colonic biopsies and negative stool tests for
infectious agents. It is unreasonable to expect the histopathol-
ogist alone to make the diagnosis (Section 4), but normal
mucosal biopsies effectively exclude active UC as a cause of
symptoms. In 10% of patients during the 5 years after initial
onset of symptoms, the diagnosis will be changed to Crohn's
disease or the diagnosis of inflammatory bowel disease
discounted. Endoscopic and histological confirmation of the
diagnosis is considered essential.104 In aminority of patients it is
not possible to characterise the cause of colitis: see Section 1.1
for correct usage of the terms ‘colitis-yet-to-be classified’ and
‘indeterminate colitis’.9,11
3.4. Investigationandprocedures toestablishadiagnosis
3.4.1. Initial investigationsECCO statement 3F
Initial laboratory investigations should include a
full blood count, serum urea, creatinine, electro-
lytes, liver enzymes, iron studies, and C-reactive
protein (CRP) [EL5, RG D]. CRP and erythrocyte
sedimentation rate (ESR) are useful markers to
monitor the response to treatment in severe colitis
[EL2b, RGB]. Microbiological testing for infectious
diarrhoea including Clostridium difficile toxin is
recommended [EL2b, RG B]. Additional stool tests
may be necessary for patients who report a recent
travel abroad [EL5, RG D]Every patient with active disease at presentation should
have a full blood count, inflammatory markers (CRP or ESR),
electrolytes and liver function tests, along with a stool sample
for microbiological testing.103 Laboratory signs of chronic
inflammation may be normal in mild or moderate distal UC.
The full blood count may reveal thrombocytosis as a result of
the chronic inflammatory response, anaemia indicating
disease severity or chronicity and leucocytosis, raising the
possibility of an infectious complication.
For UC excluding proctitis, CRP broadly correlates with
clinical activity.105–107 In patients with severe clinical
activity, an elevated CRP is generally associated with an
elevated ESR, anaemia and hypoalbuminaemia. These have
been used as predictive biomarkers to assess the need for
colectomy in acute severe coliits28,108,109 (Section 5.2.5, first
following paper in same issue). Neither CRP nor ESR is specific
enough to differentiate UC from infectious or other causes.
The initial diagnosis of UC requires the elimination of in-
fectious causes of symptomatic colitis. Stool specimens should
be cultured for common pathogens including specific assays for
Clostridium difficile toxin A and B, Campylobacter spp, and
Escherichia coli 0157:H7. Additional tests may be tailored to
the medical history, such as examination of fresh, warm stool
samples for amoebae or other parasites.
3.4.2. Microbial investigationsECCO statement 3G
In patients with an established diagnosis of UC
microbial testing is recommended in cases of
severe or refractory relapse. This includes testing
for Clostridium difficile and Cytomegalovirus
infection [EL4, RG C]
It is not routinely recommended to screen for pathogens
such as C. difficile at each flare of the disease, due to
infrequent positive results.110–112 In contrast, microbial stool
tests should be performed during refractory or severe
relapse, and in those with a history of antibiotic therapy
within an arbitrary 3 months, since C. difficile infection is
more common in these circumstances and associated with a
poor clinical outcome.113,114 Flexible sigmoidoscopy may be
superior to stool C. difficile cytotoxin assay in patients with
pseudomembranous colitis and is appropriate for patients
with diarrhoea where the stool test is negative.115
Reactivation of Cytomegalovirus (CMV) is common
in ulcerative colitis, particularly (but not invariably) in
immunosuppressed patients with severe colitis.116–118
The clinical relevance of this finding remains uncertain,
but CMV infection may cause refractory or severe relapse.
The optimal method for detecting clinically relevant CMV
infection in patients with colitis has not yet been es-
tablished. Occasional intranuclear inclusion bodies con-
sistent with CMV on histopathology do not necessarily
indicate clinically significant infection, but multiple in-
tranuclear inclusions are usually significant.119,120 CMV
should be considered in patients with refractory or severe
colitis (Section 3.5.3) and if detected, advice taken
from virologists about the significance and appropriate
therapy.
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Although faecal inflammatorymarkers are generally
not considered sufficient to be included routinely
in the diagnostic work up of UC, calprotectin, a
neutrophil-derived protein, merits further consid-
eration [EL2b, RGB]The most widely studied serological markers are peri-
nuclear anti-neutrophil cytoplasmic antibodies (pANCAs) and
anti-Saccharomyces cerevisiae antibodies (ASCA). In most
series pANCAs are found in up to 65% of patients with UC and
in less than 10% of patients with Crohn's disease. It should be
noted that the incidence of pANCA in UC may depend upon
local laboratory expertise and geographical latitude.121,122 In
view of the current limited sensitivity of these markers,
their routine use for the diagnosis of ulcerative colitis and
for therapeutic decisions is not clinically justified.123
Of the faecal markers of intestinal inflammation, neu-
trophil-derived proteins such as calprotectin, elastase,
lysozyme and lactoferin, have been evaluated in IBD.124–126
Faecal calprotectin appears to be the most sensitive, non-
invasive biomarker that reflects intestinal inflammation
in established IBD.127 However, as with all faecal tests,
calprotectin lacks the specificity to discriminate between
types of inflammation. Therefore, its use as a diagnostic tool
in UC is limited.3.4.4. Procedures recommended to establish the diagnosisECCO statement 3I
For suspected UC, colonoscopy, preferably with
ileoscopy, and segmental biopsies including the
rectum are the preferred procedures to establish
the diagnosis and extent of disease [EL5, RGD].
Patients with a severe attack should have abdom-
inal radiography and active disease confirmed by
sigmoidoscopy as a first line procedure [EL5, RGD]Colonoscopy with intubation of the terminal ileum and
segmental mucosal biopsies are preferred to sigmoidoscopy
for patients with suspected UC. The clinical context and
availability needs to be considered: colonoscopy and bowel
preparation is best avoided in patients with acute severe
colitis to avoid procedural delays and a higher risk of
perforation. Colonoscopy establishes the diagnosis and
disease extent in the large majority of cases. It appears to
be more cost-effective than index sigmoidoscopy.60,128
A plain abdominal radiograph is not a diagnostic test for
UC, but is valuable in the initial assessment of patients
with suspected severe UC (Section 3.5.3). Oesophagogas-
troduodenoscopy and mucosal biopsy are recommended in
patients with upper gastrointestinal symptoms. Wireless
capsule endoscopy (WCE) represents an advance in bowel
imaging, but large prospective studies are needed to
confirm the diagnostic relevance in ulcerative colitis.WCE is a potentially useful clinical technique for categor-
ising those patients with colitis yet to be classified,
although a normal WCE does not exclude Crohn's
disease.129
3.5. Assessment of extent, severity and activity
3.5.1. Signsofdiscontinuous inflammation inulcerativecolitisECCO statement 3J
When there is macroscopic and histological rectal
sparing, or the presence of a caecal patch in newly
diagnosed colitis evaluation of the small bowel is
indicated [EL 5, RGD]. Involvement of the appen-
dix only in left sided or extensive colitis is a
common feature of UC and requires no further
diagnostic work up to exclude CD [EL 3a, RGC]3.5.1.1. Rectal sparing and caecal patch. Macroscopic and
microscopic rectal sparing have been described in children
presenting with UC prior to treatment.130–133 In adults, a
normal or patchy inflammation in the rectum is more likely to
be due to topical or systemic therapy for UC.134,135 Patchy
inflammation in the caecum is referred to as ‘caecal patch’
and is observed in patients with left-sided colitis. The natural
history of patients with patchy right colonic inflammation
seems to be similar to those with isolated left-sided UC.136,137
Whenever there is a discontinuous pattern of inflammation in
colitis, a diagnostic work up of the small bowel is indicated to
exclude Crohn's disease.
3.5.1.2. Appendiceal skip lesions. Involvement of the
appendix as a skip lesion is reported in up to 75% of patients
with UC.93–95 Appendiceal inflammation has been associated
bothwith amore responsive course of disease and a higher risk
of pouchitis after ileal pouch anastomosis.138–141 Both findings
require confirmation.
3.5.1.3. Backwash ileitis. Continuous extension of macro-
scopic or histological inflammation from the caecum into
the most distal ileum is defined as ‘backwash ileitis’. It is
observed in up to 20% of patients with pancolitis. Rarely, ileal
erosions may occur in patients without caecal involvement
and this challenges the pathogenic theory that backwash
ileitis is caused simply by reflux of caecal contents into the
ileum.142–144 A more refractory course of ulcerative colitis
has been suggested in those with backwash ileitis.143
Additional imaging of the small bowel should be considered
in cases of macroscopic backwash ileitis, to differentiate UC
from Crohn's disease.
3.5.1.4. Small bowel. Small bowel radiology (by enterocly-
sis, follow-through, CT enteroclysis, MR enteroclysis, or WCE
(reviewed in the ECCO Consensus on diagnosis and imaging in
Crohn's disease145) is not routinely recommended. Where
there is diagnostic difficulty (rectal sparing, atypical symp-
toms, macroscopic backwash ileitis) then clinicians should
discuss imaging with an appropriate radiologist and results
viewed in the context of the clinical history.145
12 E.F. Stange et al.3.5.2. Activity indices in ulcerative colitisECCO statement 3K
Instruments for measuring clinical and/or endo-
scopic disease activity in UC are available, but
none has been subjected to an adequate valida-
tion process. In daily routine such indices are
barely used. The incorporation of a simple clinical
and/or endoscopic scoring system is desirable,
intended to improve care of UC patients and to
realise a standardised IT system for IBD. Immedi-
ate admission to hospital is warranted for all
patients fulfilling Truelove & Witts' criteria for
severe colitis to prevent delayed decision-making
which may lead to increased perioperative mor-
bidity and mortality [EL4, RGD]
Clinical, endoscopic and combined activity indices for
ulcerative colitis have been reviewed15 (Sections 1.1.2 and
2.2.2). At present, disease activity scoring for UC is the
preserve of clinical studies. However, based on the need to
standardise documentation of IBD patients on a European
level, the incorporation of a simple, valid clinical and/or en-
doscopic scoring system in electronic patient files is war-
ranted. The original classification of severe UC was proposed
by Truelove andWitts in 195513 and has stood the test of time,
because it is easy to remember and apply. This classification is
still considered to be the tool of choice to identify readily
those outpatients in need of immediate admission to hospital
and intensive treatment.146
3.5.3. Investigations for acute severe colitis on admission
Patients should have their full blood count, inflammatory
markers (C-reactive protein, or ESR), electrolytes and liver
function testsmeasured, alongwith a stool sample for culture
and assay for C. difficile toxin.146
A plain abdominal radiograph should be performed, not
only to exclude colonic dilatation (≥6.0 cm), but also to
estimate the extent of disease and look for features that
predict response to treatment. The proximal extent of
disease broadly correlates with the distal distribution of
faecal residue; in 51 episodes of severe colitis, this guide
overestimated the extent in 18% and underestimated it in
8%.108 The presence of mucosal islands (small, circular opaci-
ties representing residual mucosa isolated by surrounding
ulceration), or more than two gas-filled loops of small bowel
on the radiograph are associated with a poor response to
treatment.147,148
A flexible sigmoidoscopy should confirm the diagnosis of
severe colitis and help exclude infection, particularly with
Cytomegalovirus.116,117,149 If it is strongly suspected that
CMV might be responsible for deterioration (such as a patient
on immunomodulators in association with a high fever), it is
appropriate to request urgent histopathology. An answer
can be available within 4 h. Phosphate preparation before
flexible sigmoidoscopy is considered safe, but is probably
best avoided in patients with a dilated colon. Full colono-
scopy in patients with acute severe colitis is not recom-
mended. Purgative preparation can provoke dilatation and
colonic perforation is a real hazard of colonoscopy duringactive disease. Endoscopic criteria for severe colitis include
extensive mucosal abrasions, deep ulcerations, mucosal
detachment on the edge of these ulcerations and well-like
ulceration,150,151 but all of these can be assessed at flexible
sigmoidoscopy.3.5.4. ReassessmentofextentandseverityofulcerativecolitisECCO statement 3L
Routine colonoscopy for patients with UC in remis-
sion is unnecessary until the start of a surveillance
programme [EL5, RGD]. Endoscopic reassessment is
appropriate at a relapse, or for steroid-dependent
or -refractory UC or when considering colectomy
[EL5, RGD]
Despite the importance of disease location in determining
the prognosis, the risk of cancer and the choice of therapy,
the appropriateness of periodic restaging after index colo-
noscopy has never been studied. The value of endoscopic
reassessment of disease extent prior to a surveillance
programme is much debated. Consequently ECCO statement
3L only represents expert opinion. Colonoscopy is more sen-
sitive than barium studies for estimating disease extent, but
the risk of malignancy is historically based on contrast studies
and colonoscopy defines a different extent to histopathol-
ogy.60,152–154 Chromoendoscopy better correlates with the
disease extent determined by histopathology, but the pro-
cedure is time consuming and requires a level of expertise not
universally available.155 Drug-induced clinical remission may
not be associated with endoscopic or histological remission,
but the prognostic implications of endoscopic re-evaluation
in quiescent disease have yet to be determined.60 The area
calls for systematic study.3.6. Endoscopy, ultrasound and colonography
3.6.1. Endoscopic features of ulcerative colitisECCO statement 3M
No endoscopic feature is specific for UC. The most
useful endoscopic features of UC are considered to
be continuous and confluent colonic involvement
with clear demarcation of inflammation and rectal
involvement. [EL2b, RGB] Endoscopic severity of
UC may be best reflected by the presence of
mucosal friability, spontaneous bleeding and deep
ulcerations [EL2b, RGB]
Endoscopic changes characteristically commence proximal
to the anal verge and extend proximally in a continuous, con-
fluent and concentric fashion. The demarcation between in-
flamedandnormal areas is usually clear andmay occur abruptly
within millimetres, especially in distal disease. The endoscopic
features of mild inflammation are erythema, vascular con-
gestion of the mucosa and loss of visible vascular pattern.
Moderately active colitis is characterised by a coarse granular
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to light touch). Severe colitis is characterised by spontaneous
bleeding and ulceration (Table 1.3).60,154,156 The choice of
endoscopic score is complex and has been reviewed.15,157 In
contrast to Crohn's disease, ulcers in severe UC are always em-
bedded in inflamed mucosa. The presence of deep ulcerations
is a poor prognostic sign.154 In longstanding disease, mucosal
atrophy can result in loss of haustral folds, luminal narrowing
and pseudopolyps.3.6.2. Abdominal ultrasound and scintigraphy in
ulcerative colitisECCO statement 3N
Transabdominal and hydrocolonic ultrasound are
of secondary value for defining the extent of UC
[EL3, RGC]. Doppler ultrasound is a complemen-
tary technique for assessing disease activity in
expert hands [EL2b, RGD]
Abdominal ultrasound screens for small bowel or colonic
inflammation with a sensitivity of 80–90%. Ultrasound has the
advantage of being low cost and non-invasive, but the
accuracy is very much dependent on the skill of the operator
and there is low specificity for differentiating UC from other
causes of colonic inflammation.160–162 Hydrocolonic ultra-
sound (abdominal ultrasonography in conjunction with retro-
grade instillation of water in the colon) has a high sensitivity
for identifying active colitis, but the method is too cumber-
some for day to day clinical practice.163 Doppler ultrasound
of the superior and inferior mesenteric arteries has been
used to evaluate disease activity and risk of relapse. It should
not, however, be considered a standard procedure.164,165 For
this method to be viable, further prospective, multi-centre
studies are needed.
Leukocyte scintigraphy is safe, non-invasive and poten-
tially allows assessment of the presence, extent and activity
of inflammation, but the method lacks specificity.166,167 It is
unreliable if patients are taking steroids. Novel markers to
detect intestinal inflammation which are not associated with
exposure to radiation are being developed.3.6.3. Virtual colonography in ulcerative colitisECCO statement 3O
Virtual colonography is an evolving technology.
The limited data currently available do not
demonstrate a diagnostic value for assessing the
disease extent in patients with suspected or
proven UC [EL 4, RGC]
Few studies on a limited number of patients have inves-
tigated MR-colonography or CT-colonography in UC. The
results are conflicting and subtle changes of the mucosa such
as erosions or flat polyps are insufficiently visualized.168–170
Because of these limitations, virtual colonoscopy is no
alternative to standard colonoscopy in patients with UC at
present.3.7. Colonic stenosis in ulcerative colitis
ECCO statement 3P
Each colonic stenosis in UC should raise the sus-
picion of colorectal carcinoma. Multiple biopsies
should be taken and a surgical opinion should be
sought. When endoscopic intubation of the colon is
not possible, imaging procedures, such as double
contrast barium enema, CT and/or MRI colonogra-
phy may be employed [EL5, RGD]
In longstanding ulcerative colitis, a colonic stricture
signifies an increased risk for colorectal carcinoma and
requires histological and surgical expertise.171 If colonoscopy
is incomplete due to stricture, then double or even single
contrast barium enema is the first choice procedure.172 CT
colonography can reveal the mucosal pattern and colitis
proximal to a stricture but may not identify all lesions seen on
colonoscopy.173
4. Histopathology
4.1. General
In ulcerative colitis, histopathology is used for diagnosis, the
assessment of disease activity and the identification of intra-
epithelial neoplasia (dysplasia). The latter will be addressed
separately.
4.1.1. Considerations
Several factors have influenced the accuracy of the histo-
pathological diagnosis of ulcerative colitis, as it has in Crohn's
disease. The advent of colonoscopy as the diagnostic proce-
dure of choice has had consequences. It has allowed the
analysis of multiple biopsies from different segments of the
colon. More biopsies are obtained, often early in the evolution
of the disease. Furthermore, biopsies can be obtained in young
children presenting with bloody diarrhoea. In addition, the
introduction of new therapies inducing mucosal healing has
made the pathologists aware of the impact of treatment upon
the microscopic features. This has changed the approach to
histopathological diagnosis in the past decade.
4.1.2. Evaluation of the literature
Articles reporting original research into the reproducibility,
sensitivity, specificity and predictive value of individual
features useful for the histopathological diagnosis of ulcerative
colitis were sought from the literature, using Medline and
Pubmed. As selection criteria, only those features which
achieved moderate reproducibility judged by the kappa
statistic, or findings confirmed by several studies were con-
sidered. In addition, we have reviewed studies describing and
defining diagnostic microscopic features.174–193 The literature
canbedivided into groups, dependingupon thenumber (one, or
multiple) of biopsies examined, or the duration of the disease.
In ten studies multiple biopsies were examined (including two
comparing the diagnostic value of both single and multiple
biopsies).184–193
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be divided. The first group is composed of studies with
biopsies obtained in patients with an established diagnosis
of ulcerative colitis, based on extended clinical follow up.
Disease duration varies between 6±3weeks and 12 years.186–189
In these studies patients with doubtful criteria were generally
excluded.177,178,186 A second group is composed of retrospective
studies without clear data on the duration of the disease. These
papers are retrospective studies and can be pooled with the
first group, because the diagnosis is again established through
a period of follow up. A third group applies to studies on bi-
opsies obtained early after onset of the disease, before
treatment.181,183,190,191,193 For early onset disease, the duration
of disease varies between 4 and 14 days (3.69±0.52 days after
the appearance of rectal bleeding, or 10 days after initial
symptoms).179,181,185 In these studies, the diagnosis was subse-
quently confirmed by follow up of the patients and are pro-
spective studies. Children aremainly included in the third group.
4.2. Microscopic features — definitions
A large number of microscopic features have been evalu-
ated. They can be broadly classified into
• architectural features
• epithelial abnormalities, and
• inflammatory features.
Architectural features include crypt branching, crypt
distortion, crypt atrophy and surface irregularity. Epithelial
cell abnormalities are mucin depletion and Paneth cell
metaplasia. Inflammatory features include increased lamina
propria cellularity, basal plasmacytosis, basal lymphoid ag-
gregates, lamina propria eosinophils.
4.2.1. Crypt architectural abnormalities
Crypt branching: two ormore branched (bifurcated) crypts in a
well oriented section, whether the branching is in the vertical
or horizontal axis.178,181,182,190,194 When applied to a single
crypt, the feature is less specific.182 The pathogenesis can be
accounted for by regeneration following previous damage or
destruction (cryptolysis).
Mucosal (crypt) distortion: irregularities in crypt size (i.e.
variable diameter), spacing, orientation (i.e. loss of paralle-
lism), or shape (including branching with a cystic configura-
tion).185–187,190, 191,181,182,193,194 In some studies this includes
separation from the underlying muscularis mucosae.181,185
Samples from the anal transition zone or columnar cuff (some-
times wrongly termed “low rectal biopsies”) are not suitable for
the assessment of crypt branching or mucosal distortion.
Mucosal (crypt) atrophy and crypt density: a combina-
tion of crypt depletion (thinned-out crypts, generally
recognised by a distance of more than one crypt diameter
between crypts) and an increase in the distance bet-
ween the muscularis mucosae and the base of the
crypts.177,181,194 Some authors emphasise either crypt
depletion185 or an increased distance between the
muscularis mucosae and the base of the crypts190 rather
than both features. An increase in the intercryptal space
and the crypt–muscularis mucosae distance may be
normal in the caecum and distal rectum.194 The distance
between the muscularis mucosae and the crypt baseshould not be evaluated in the vicinity of lymphoid
follicles. The pathogenesis can be explained as a con-
sequence of crypt death from disease. If all crypt cells
die, crypts cannot regenerate and disappear within 48 h in
experimental animals. However, if one or more clonogenic
cells survive the insult, rapid proliferation regenerates
the crypt within 72–96 h in experimental animals. The
mucosa subsequently heals by clonal expansion and the
number of crypts that survive to regenerate following a
cytotoxic insult correlates with symptom severity in
animal models. A number of growth factors affect crypt
regeneration in murine models.195 Nevertheless, it
remains unclear what size of (uncrushed) biopsy is
adequate for proper evaluation and how many levels of
the biopsy need to be examined properly to evaluate
atrophy.
Surface irregularity: Surface irregularity (synonyms include
villous surface, villiform surface, or villous mucosa)182,185
means wide crypt mouths, giving the mucosal surface a finger-
like appearance.181 The impression is due to separation of
crypts177 and a semantic distinction between “irregular
surface” and “villous surface” has been proposed, according
to the villous–crypt ratio.186
4.2.2. Epithelial cell abnormalities
Paneth cell metaplasia: Paneth cells are normally extremely
uncommon in the colon distal to the splenic flexure, being
present in 0–1.9% of non-IBD controls.196 The presence of
Paneth cells in the distal colon can be termed Paneth cell
metaplasia. The pathogenesis is related to epithelial regen-
eration and repair.196
Mucin depletion: defined as a reduction in number of
goblet cells or depleted mucin within cells.194
4.2.3. Inflammatory features
Basal plasmacytosis: defined either as the presence of plasma
cells around (deep 1/5th of the lamina propria) or below the
crypts, alongside or penetrating the muscularis mucosae.
Basal plasmacytosis is also referred to as subcryptal plasma
cells,185 plasmacytosis with extension in the base of the
mucosa,193 or accumulation of plasma cells between the base
of the crypts and themuscularis mucosae.190 The abnormality
can be focal or diffuse and subcryptal location of the cells is
not always present.181,185
Lamina propria cellularity: evaluated according to
density, composition and distribution. An increase in the
total number of plasma cells, lymphocytes, histiocytes and
eosinophils is a feature of all types of colorectal
inflammation194 and is of limited discriminant value. In
ulcerative colitis the cellular infiltrate is diffuse and
transmucosal.
Increased density has been described as “a subjectively
abnormal” infiltrate,182, a “prominent” increase (assessed
by widening of the intercryptal space by the inflammatory
infiltrate177 or simple “hypercellularity”.185 The increase is
difficult to quantify. Increased lamina propria cellularity
may also be absent in quiescent disease, following treat-
ment, or in the natural course of the disease.178,24 Further-
more, increased lamina propria cellularity may persist in
infective colitis197 and is a normal feature of caecal
biopsies.
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dilemmas. Some authors discriminate between an
increase in neutrophils alone and an increase in both
round cells and neutrophils. Neutrophils may be present in
the lamina propria or between epithelial cells, are readily
recognised and a reproducible feature of inflammation.177
More than three neutrophils in the lamina propria outside
capillaries may be abnormal,186 but the exact number has
not been agreed. Neutrophils are a feature of cryptitis
with migration of neutrophils through the crypt epithe-
lium, inducing crypt disruption and crypt abscesses, which
may be responsible for cell surface damage or disruption.
The diagnostic value of neutrophils in ulcerative colitis,
however, is limited because they are also present in
infective colitis and other forms of colitis.177,185 In
contrast, eosinophils in the lamina propria are highly
variable. An increase has been noted in ulcerative colitis
and a potential diagnostic value has been proposed,
but data were obtained from studies of longstanding
disease.178,187
The distribution of the lamina propria cellular inflamma-
tory infiltrate has been divided into: focal (normal back-
ground cellularity with areas of increased cellularity);
patchy (abnormal background cellularity with variable
intensity); and diffuse (abnormal background cellularity
with an overall increase in density). These terms are
preferred. Confusion is caused when the term “discontin-
uous” is used to describe both focal and patchy changes in
some studies,194 or used as a synonym for focal in others.187 A
diffuse increase can be either superficial (confined to the
superficial and middle thirds of the lamina propria) or
transmucosal (usually maximal in the lower third). The
distribution can be evaluated in a single sample or between
multiple samples from the same site. To avoid diagnostic
error, the criteria of diffuse transmucosal inflammation for
diagnosing ulcerative colitis should be avoided in biopsies
from early onset disease in children,193 or after treat-
ment and when disease is resolving or quiescent. In
these circumstances the biopsy may be normal or show
focal changes.189,198,199
Basal lymphoid aggregates: nodular collections of lym-
phocytes between the crypt base and muscularis muco-
sae,182 without germinal centres.177,182,186,194 At least two
aggregates are needed for this feature to be considered
abnormal.177,186,194
Stromal changes: diffuse thickening of the muscularis
mucosae or a double muscularis mucosae (which is unusual,
but characteristic when present) have been observed in
longstanding active and quiescent ulcerative colitis.200
Backwash ileitis: ileal inflammation in ulcerative colitis
is called backwash ileitis, despite the fact that the
backwash or reflux pathogenesis has never been estab-
lished. ‘Backwash ileitis’ should be in continuity with
colonic inflammation (see also Section 3.5.1) and the
lesions in the caecum should show a similar, or greater
degree of active inflammation. The ileal lesions in ‘back-
wash ileitis’ are characterised by active inflammation in
the villi and lamina propria, together with shortening and
blunting of the villi. Focal, isolated ileal erosions, mucous
gland metaplasia or patchy oedema with mild ac-
tive inflammation are features suggestive of Crohn's
disease.201,202ECCO Statement 4A
For a reliable diagnosis of ulcerative colitis multiple
biopsies from five sites around the colon (including
the rectum) and the ileum should be obtained.
Multiple implies a minimum of two samples [EL1b,
R GB]
ECCO Statement 4B
Biopsies should be accompanied by clinical infor-
mation including the age of the patient, duration
of disease and duration and type of treatment
[EL1b, R GB]. Biopsies from different regions
should be handled in such a way that the region of
origin can be identified [EL1c RGA]. This can be
done by using different containers, multiwell
cassettes, or an acetate strip [EL5, RG D]. All
tissue samples should be fixed immediately by
immersion in buffered formalin or an equivalent
solution prior to transport. It is recommended
that multiple sections from each sample are
examined [EL5, R G D]4.3. Microscopic features— appraisal of the diagnosis
4.3.1. Early stage disease
It has been proposed that a non-specific increase in the
inflammatory infiltrate in the lamina propria in combination
with absent crypt architectural distortion, indicates a diag-
nosis of acute, infective colitis177,185 rather than ulcerative
colitis. This finding, however, is not confirmed in those
studies of patients with early onset colitis (within 10 days of
symptoms, Section 4.1.2).179,203
ECCO Statement 4C
Basal plasmacytosis at the initial onset has a high
predictive value for the diagnosis of IBD [EL 3, RG
C]. Repeat biopsies after an interval may help to
solve differential diagnostic problems and estab-
lish a definitive diagnosis especially in adults, by
showing additional features [EL 5, RG D]Basal plasmacytosis is observed in biopsies obtained at early
onset in 38–100% of adult patients181,185 and 58% of children
with ulcerative colitis.17 It is particularly a feature in young
children; in these cases it is notably present in rectal biopsies
and decreases proximally. It is an early feature, sometimes the
first lesion to appear181,185,190,191,193 and a good predictive
marker.
Glandular abnormalities can be identified with good (83–
90%) interobserver agreement.176,186,204 According to most
studies, diffuse crypt architectural irregularity and reduced
crypt numbers or atrophy indicate ulcerative colitis.178,194
Nevertheless, these features may still not be present in
16 E.F. Stange et al.biopsies obtained from patients with colitis at an early
stage.181 Crypt architectural changes were observed in
biopsies obtained between 16 and 30 days after onset,181
but not in earlier biopsies. In another study185 abnormal
architecture was found in all biopsies obtained within days of
onset, but in this study disease onset was defined by loss of
blood and not by other symptoms. Crypt distortion and
mucosal atrophy may return to normal or remain unchanged
after resolution of symptoms.198,199
ECCO Statement 4D
In young children or patients with an aberrant pre-
sentation of colitis, UC should always be considered
in the differential diagnosis even if the pathology is
not typical [EL1b RG B]Reliable diagnostic features may be absent from biopsies
obtained in early onset disease, in acute severe colitis, or in
patients with an atypical immunological response (such as
young children, or patientswith primary sclerosing cholangitis).
The routine use of additional techniques such as immunohis-
tochemistry is not recommended at present.4.3.2. Established diseaseECCO Statement 4E
A diagnosis of established ulcerative colitis is based
upon the combination of: basal plasmacytosis
(defined as presence of plasma cells around (deep
part of the lamina propria) or below the crypts
(subcryptal)), heavy, diffuse transmucosal lamina
propria cell increase and widespread mucosal or
crypt architectural distortion [EL 1a, RG A]
The exact number of features needed for diagnosis has
not been established. A correct diagnosis of ulcerative colitis
is reached in approximately 75% of the cases when two or
three of the four features, severe crypt architectural
distortion, severe decreased crypt density, irregular surface
and heavy diffuse transmucosal inflammation are present, in
the absence of genuine granulomas.186,191
ECCO Statement 4F
Widespread mucosal or crypt architectural distor-
tion, mucosal atrophy and a villous or irregular
mucosal surface appear later during the evolution
of the disease (4 weeks or more). They suggest a
diagnosis of ulcerative colitis in established dis-
ease [EL 2, RG B]In established ulcerative colitis a villous surface is present
in 17–63% of the cases (compared to 0–24% for Crohn'sdisease and 0–7% for infective colitis).194 The lesion is
observed in approximately one third of the initial biopsies of
children with ulcerative colitis.190 In adults this feature
was present in approximately 23% of the patients presenting
16–30 days after the initial symptoms, but not in earlier
biopsies.181ECCO Statement 4G
Basal plasmacytosis is a good diagnostic feature in
established ulcerative colitis [EL 2, RG B]. A heavy,
diffuse transmucosal lamina propria cell increase
is a good diagnostic feature in established active
disease [EL 2, RG B]. Distribution of inflammation
along the colon, with a decreasing gradient of
inflammation from distal to proximal is in favour
of a diagnosis of ulcerative colitis in an untreated
patient [EL5 RG D]The diagnostic value of basal plasmacytosis is confirmed
by studies of biopsies obtained in established disease, being
present in up to 63% of cases.186 The feature is rare in non-
IBD colitis,182 but it is also common in Crohn's disease.
Basal plasmacytosis decreases and can disappear during
treatment.
A heavy, diffuse, transmucosal, lamina propria cell
infiltrate favours a diagnosis of ulcerative colitis,194 but
patchy inflammation178 can occasionally be seen in
ulcerative colitis or, when multiple biopsies are examined,
a single piece may have evidence of chronic colitis and
others have normal mucosa.190,198,205 The heavy, diffuse
transmucosal lamina propria cell increase can be absent in
young children (b12 years). It can decrease in intensity
and become patchy during the natural evolution of the
disease or subsequent to treatment. This feature is
therefore mainly useful for the diagnosis in established
disease. Its absence does not exclude a diagnosis of
ulcerative colitis.ECCO Statement 4H
General or widespread crypt epithelial neutrophils
(cryptitis and crypt abscesses) favour ulcerative
colitis. However these lesions may occur in
infections and other types of colitis [EL 2b,
RG B]. Lamina propria and intraepithelial neutro-
phils are absent in inactive or quiescent disease [EL
2b, RG B]
General or widespread crypt epithelial neutrophils favour
a diagnosis of ulcerative colitis, but crypt abscesses and
cryptitis can also occur in infective colitis, although they are
less prominent.18 Neutrophils are absent during inactive or
quiescent disease.
Basal lymphoid aggregates favour a diagnosis of estab-
lished ulcerative colitis, butmay occur in Crohn's colitis177,182
and are not useful in early onset disease.
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Paneth cell metaplasia distal to the splenic flexure
is a non-specific feature. It is suggestive of a
diagnosis of ulcerative colitis in established dis-
ease [EL 3, RG C]. Severe, widespread mucin
depletion is helpful for the diagnosis of ulcerative
colitis in active disease [EL 3, RG C]
Paneth cell metaplasia favours a diagnosis of ulcerative
colitis.187 Thepredictive value is highbut the sensitivity is low.182
It is not seen in biopsies obtained early in the disease177,181 and
appears to be related to established disease.196 Mucin depletion
also favours a diagnosis of ulcerative colitis. It correlates with
disease activity, so is a helpful, but not pivotal diagnostic
feature.193 Mucinpreservation inassociationwithactivedisease,
however, may favour a diagnosis of Crohn's disease rather than
ulcerative colitis.188
4.4. Microscopic features — disease activity
ECCO Statement 4J
The pathology report should give an indication of
the activity of the disease [EL5 RG D]
Disappearance of mucosal inflammation following treat-
ment has been observed,199 so biopsies are also used for
distinguishing between quiescent and active disease, as well
as different grades of activity. Scoring systems have been
introduced for the assessment of disease activity, particularly
for therapeutic trials. The potential value of histopathology
for predicting relapse and evaluating adequate control of
inflammation has implications for therapeutic management
and reducing the risk of neoplasia. Both epithelial damage in
association with neutrophils and basal plasmacytosis have
been proposed as markers of disease activity and the
prediction of relapse.206–209 The scope of this text does not
permit detailed analysis of these scoring systems.
4.5. Conclusions
The evolution of the microscopic features that are useful for a
diagnosis of ulcerative colitis is a time and disease-activity
dependent process. This notion is confirmed by experimental
studies. In early onset disease, few or no characteristic features
may be present. In established disease the diagnosis can be based
upon a combination of basal plasmacytosis, crypt architectural
abnormalities, diffuse transmucosa inflammatory infiltrate and
epithelial surface irregularity. The natural evolution from active to
quiescent disease and treatment also have an impact on
microscopic features. In quiescent disease, few features may
persist,neutrophils arenotablyabsentandbiopsiesmaybenormal.
It appears important to distinguish between different
situations for the diagnosis of ulcerative colitis:
• Biopsies obtained during the initial phase of the disease
(within two weeks of onset of symptoms, including young
children and without treatment)• Biopsies obtained from patients with established disease
before treatment (symptoms for more than 4–6 weeks)
• Biopsies obtained from patients with established dis-
ease after treatment (examination of previous biopsies is
desirable).
In every patient, including children, the diagnostic yield
can be increased when multiple biopsies from different
segments of the colon are examined, including the rectum
and the ileum, although these should be carefully labelled
for proper assessment.191,192,210,211
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